In: Adam MP, Ardinger HH, Pagon RA (eds) GeneReviews
Imbruvica (ibrutinib) Disease area(s): Oncology/hematology Manufacturer(s): AbbVie/Johnson & Johnson 2024 Sales (USD): $6.39 billion Why it sold so well: In 2024, Johnson & Johnson saw a 7% decline in global revenues of Imbruvica, primarily due to decreased demand and lower market share in the US, as well as reduced collaboration revenues internationally
They can also contribute to a loss of lean muscle mass, making physical activity especially important for maintaining strength and overall health
Differentiation (1985) 29(3):1958.10.1111/j.1432-0436.1985.tb00316.x 171 OhlssonCBengtssonBAIsakssonOGAndreassenTTSlootwegMC
Lolachi, she really smart and she cares about her patients
This has been accomplished, CEO Mahoney explains, through a lot of digital advertising across all the major channels -- and by working very closely with them in terms of policy compliance